Glances in Immunology of HIV and HCV Infection

Overview

Journal Adv Virol

Publisher Wiley

Specialty Microbiology

Date 2012 Jul 4

PMID 22754568

Citations 5

Authors

Maria Giovanna Quaranta

Benedetta Mattioli

Stefano Vella

Affiliations

Soon will be listed here.

Abstract

Since the identification of HIV and HCV much progress has been made in the understanding of their life cycle and interaction with the host immune system. Despite these viruses markedly differ in their virological properties and in their pathogenesis, they share many common features in their immune escape and survival strategy. Both viruses have developed sophisticated ways to subvert and antagonize host innate and adaptive immune responses. In the last years, much effort has been done in the study of the AIDS pathogenesis and in the development of efficient treatment strategies, and a fatal infection has been transformed in a potentially chronic pathology. Much of this knowledge is now being transferred in the HCV research field, especially in the development of new drugs, although a big difference still remains between the outcome of the two infections, being HCV eradicable after treatment, whereas HIV eradication remains at present unachievable due to the establishment of reservoirs. In this review, we present current knowledge on innate and adaptive immune recognition and activation during HIV and HCV mono-infections and evasion strategies. We also discuss the genetic associations between components of the immune system, the course of infection, and the outcome of the therapies.

Citing Articles

Human defensins and Th-1 cytokines in hepatitis C viral infection.

Owusu D, Owusu M, Owusu B Pan Afr Med J. 2021; 37:103.

PMID: 33425136 PMC: 7757282. DOI: 10.11604/pamj.2020.37.103.25211.

Spontaneous clearance of hepatitis C virus after liver transplantation: a report of four cases.

Tamaki I, Kaido T, Yagi S, Ueda Y, Hatano E, Okajima H Surg Case Rep. 2016; 1(1):124.

PMID: 26943448 PMC: 4690824. DOI: 10.1186/s40792-015-0127-0.

Viral (hepatitis C virus, hepatitis B virus, HIV) persistence and immune homeostasis.

Zhou Y, Zhang Y, Moorman J, Yao Z, Jia Z Immunology. 2014; 143(3):319-30.

PMID: 24965611 PMC: 4212946. DOI: 10.1111/imm.12349.

Assessment of HTLV-I proviral load, HIV viral load and CD4 T cell count in infected subjects; with an emphasis on viral replication in co-infection.

Rahimi H, Rezaee S, Valizade N, Vakili R, Rafatpanah H Iran J Basic Med Sci. 2014; 17(1):49-54.

PMID: 24592307 PMC: 3938886.

Emergence of a norovirus GII.4 strain correlates with changes in evolving blockade epitopes.

Lindesmith L, Costantini V, Swanstrom J, Debbink K, Donaldson E, Vinje J J Virol. 2012; 87(5):2803-13.

PMID: 23269783 PMC: 3571402. DOI: 10.1128/JVI.03106-12.

References

Groot F, van Capel T, Kapsenberg M, Berkhout B, de Jong E . Opposing roles of blood myeloid and plasmacytoid dendritic cells in HIV-1 infection of T cells: transmission facilitation versus replication inhibition. Blood. 2006; 108(6):1957-64. DOI: 10.1182/blood-2006-03-010918. View

Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N . Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41(10):1105-9. DOI: 10.1038/ng.449. View

Younes S, Yassine-Diab B, Dumont A, Boulassel M, Grossman Z, Routy J . HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med. 2003; 198(12):1909-22. PMC: 2194146. DOI: 10.1084/jem.20031598. View

Hussain L, Lehner T . Comparative investigation of Langerhans' cells and potential receptors for HIV in oral, genitourinary and rectal epithelia. Immunology. 1995; 85(3):475-84. PMC: 1383923. View

Lehner T, Wang Y, Pido-Lopez J, Whittall T, Bergmeier L, Babaahmady K . The emerging role of innate immunity in protection against HIV-1 infection. Vaccine. 2008; 26(24):2997-3001. DOI: 10.1016/j.vaccine.2007.11.060. View

Easterbrook P . Long-term non-progression in HIV infection: definitions and epidemiological issues. J Infect. 1999; 38(2):71-3. DOI: 10.1016/s0163-4453(99)90071-3. View

Cadogan M, Dalgleish A . HIV immunopathogenesis and strategies for intervention. Lancet Infect Dis. 2008; 8(11):675-84. DOI: 10.1016/S1473-3099(08)70205-6. View

Eggena M, Barugahare B, Jones N, Okello M, Mutalya S, Kityo C . Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol. 2005; 174(7):4407-14. DOI: 10.4049/jimmunol.174.7.4407. View

Dong C . TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol. 2008; 8(5):337-48. DOI: 10.1038/nri2295. View

10.

Chen M, Sallberg M, Sonnerborg A, Weiland O, Mattsson L, Jin L . Limited humoral immunity in hepatitis C virus infection. Gastroenterology. 1998; 116(1):135-43. DOI: 10.1016/s0016-5085(99)70237-4. View

11.

Oh D, Baumann K, Hamouda O, Eckert J, Neumann K, Kucherer C . A frequent functional toll-like receptor 7 polymorphism is associated with accelerated HIV-1 disease progression. AIDS. 2008; 23(3):297-307. DOI: 10.1097/QAD.0b013e32831fb540. View

12.

Sun L, Finnegan C, Kish-Catalone T, Blumenthal R, Garzino-Demo P, La Terra Maggiore G . Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. J Virol. 2005; 79(22):14318-29. PMC: 1280242. DOI: 10.1128/JVI.79.22.14318-14329.2005. View

13.

Khakoo S, Thio C, Martin M, Brooks C, Gao X, Astemborski J . HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science. 2004; 305(5685):872-4. DOI: 10.1126/science.1097670. View

14.

Shin E, Seifert U, Kato T, Rice C, Feinstone S, Kloetzel P . Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J Clin Invest. 2006; 116(11):3006-14. PMC: 1592549. DOI: 10.1172/JCI29832. View

15.

Mogensen T, Melchjorsen J, Larsen C, Paludan S . Innate immune recognition and activation during HIV infection. Retrovirology. 2010; 7:54. PMC: 2904714. DOI: 10.1186/1742-4690-7-54. View

16.

Woltman A, Boonstra A, Janssen H . Dendritic cells in chronic viral hepatitis B and C: victims or guardian angels?. Gut. 2009; 59(1):115-25. DOI: 10.1136/gut.2009.181040. View

17.

Cucchiarini M, Kammer A, Grabscheid B, Diepolder H, Gerlach T, Gruner N . Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection. Cell Immunol. 2000; 203(2):111-23. DOI: 10.1006/cimm.2000.1683. View

18.

Bjoro K, Froland S, Yun Z, Samdal H, Haaland T . Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med. 1994; 331(24):1607-11. DOI: 10.1056/NEJM199412153312402. View

19.

Buchbinder S, Katz M, Hessol N, OMalley P, Holmberg S . Long-term HIV-1 infection without immunologic progression. AIDS. 1994; 8(8):1123-8. DOI: 10.1097/00002030-199408000-00014. View

20.

Kanto T, Inoue M, Miyatake H, Sato A, Sakakibara M, Yakushijin T . Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection. J Infect Dis. 2004; 190(11):1919-26. DOI: 10.1086/425425. View